Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last 1,167 INR
Change Today 0.00 / 0.00%
Volume 0.0
As of 7:05 AM 07/3/15 All times are local (Market data is delayed by at least 15 minutes).

astrazeneca pharma india ltd (ASTR) Snapshot

Open
1,190
Previous Close
1,179
Day High
1,210
Day Low
1,150
52 Week High
06/16/15 - 1,299
52 Week Low
12/17/14 - 781.00
Market Cap
29.2B
Average Volume 10 Days
61.7K
EPS TTM
-8.34
Shares Outstanding
25.0M
EX-Date
07/9/12
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for ASTRAZENECA PHARMA INDIA LTD (ASTR)

Related News

No related news articles were found.

astrazeneca pharma india ltd (ASTR) Related Businessweek News

No Related Businessweek News Found

astrazeneca pharma india ltd (ASTR) Details

AstraZeneca Pharma India Limited, a biopharmaceutical company, manufactures, distributes, and markets pharmaceutical products in India and internationally. The company primarily offers products in the areas of cardiovascular and metabolic diseases; oncology; respiratory, inflammation, and autoimmunity; and infection, neuroscience, and gastrointestinal diseases. It also provides clinical trial services on pharmaceutical products. The company was founded in 1979 and is headquartered in Bengaluru, India. AstraZeneca Pharma India Limited is a subsidiary of AstraZeneca Pharmaceuticals AB.

Founded in 1979

astrazeneca pharma india ltd (ASTR) Top Compensated Officers

Managing Director, Director, Member of Share ...
Total Annual Compensation: 12.3M
Compensation as of Fiscal Year 2014.

astrazeneca pharma india ltd (ASTR) Key Developments

AstraZeneca Pharma India Enters into Distribution Services Agreement with Sun Pharmaceutical Industries

AstraZeneca Pharma India has entered into a distribution services agreement with Sun Pharmaceutical Industries for AstraZeneca's brand 'Axcer', a new brand of ticagrelor, a drug used for the treatment of acute coronary syndrome (ACS). AZPIL already has a brand under the trademark 'Brilinta', for ticagrelor molecule, launched and marketed by AZPIL in India since 2012. Sun Pharma will be promoting and distributing 'Axcer' brand in India. This collaboration enables AstraZeneca to expand usage of this molecule through wider reach to physicians and thereby benefiting a greater number of ACS patients. It strengthens Sun Pharma's cardiology portfolio with the addition of a new patented therapy.

Dr Reddy's Laboratories Limited and Astrazeneca Pharma India Limited Enter Distribution Agreement

Dr. Reddy's Laboratories Ltd. and AstraZeneca Pharma India Limited entered into a distribution agreement for Riax, a new brand of saxagliptin and Riax-M a fixed dose combination with metformin, in Type 2 Diabetes. Both Riax and Riax M are trademarks of the AstaZenca Group.

AstraZeneca Pharma India Limited Reports Audited Standalone Earnings Results for the Fourth Quarter and Full Year Ended March 31, 2015

AstraZeneca Pharma India Limited reported audited standalone earnings results for the fourth quarter and full year ended March 31, 2015. For the quarter, the company reported total income from operations (net) of INR 1,685.503 million compared to INR 1,141.522 million a year ago. Profit from operations before other income, finance costs and exceptional items was INR 367.837 million compared to loss from operations before other income, finance costs and exceptional items of INR 178.742 million a year ago. Profit from ordinary activities before tax was INR 381.294 million compared to loss from ordinary activities before tax of INR 25.688 million a year ago. Net profit for the period was INR 381.294 million or INR 15.25 per basic and diluted share, compared to net loss of INR 25.688 million or INR 1.03 per basic and diluted share, a year ago. For the year to date, the company reported total income from operations (net) of INR 5,170.694 million compared to INR 4,739.710 million a year ago. Loss from operations before other income, finance costs and exceptional items was INR 266.881 million compared to INR 230.975 million a year ago. Loss from ordinary activities after tax was INR 208.398 million compared to INR 5.089 million a year ago. Net loss for the period was INR 208.398 million or INR 8.34 per basic and diluted share, compared to INR 5.089 million or INR 0.20 per basic and diluted share, a year ago.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
ASTR:IN 1,167.35 INR -11.95

ASTR Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for ASTR.
View Industry Companies
 

Industry Analysis

ASTR

Industry Average

Valuation ASTR Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 6.1x
Price/Book 19.1x
Price/Cash Flow NM Not Meaningful
TEV/Sales 6.1x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact ASTRAZENECA PHARMA INDIA LTD, please visit www.astrazenecaindia.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.